Cortexyme, a Phase 1b biotech developing therapies for Alzheimer’s disease, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol CRTX. Cortexyme filed confidentially on March 4, 2019. BofA Merrill Lynch and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.